26.32

5.56% -1.55

After Hours: 25.98 -0.34 -1.29%

Beam Therapeutics Inc (BEAM)

Overview News Price History Option Chain Financials Why BEAM Down? Discussions Forecast

Beam Therapeutics Inc stock is traded at $26.32, with a volume of 4.68M. It is down -5.56% in the last 24 hours and up +32.39% over the past month. Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Previous Close:

$27.87

Open:

$28.48

24h Volume:

4.68M

Relative Volume:

1.83

Market Cap:

$2.66B

Revenue:

$352.57M

Net Income/Loss:

$-143.01M

P/E Ratio:

-14.54

EPS:

-1.81

Net Cash Flow:

$-153.40M

1W Performance:

+2.21%

1M Performance:

+32.39%

6M Performance:

+79.90%

1Y Performance:

+14.29%

1-Day Range:

$25.62

$28.62

1-Week Range:

$24.67

$28.75

52-Week Range:

$13.53

$35.25

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name

Beam Therapeutics Inc

Sector

Healthcare (1141)

Industry

Biotechnology (637)

Phone

857-327-8775

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

509

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

BEAM's Discussions on Twitter

Compare BEAM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BEAM Beam Therapeutics Inc	26.32	2.82B	352.57M	-143.01M	-153.40M	-1.81
VRTX Vertex Pharmaceuticals Inc	407.79	106.37B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	460.46	59.90B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	564.63	60.40B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	796.92	49.56B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.10	36.88B	4.56B	-176.77M	225.30M	-1.7177

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-25	Initiated	Jefferies	Buy
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Dec-08-23	Downgrade	Jefferies	Buy → Hold
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Dec-13-22	Initiated	Citigroup	Buy
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Apr-28-22	Initiated	Credit Suisse	Neutral
Jan-05-22	Initiated	Guggenheim	Buy
Oct-19-21	Initiated	SVB Leerink	Outperform
Sep-24-21	Resumed	Stifel	Buy
Sep-10-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Redburn	Buy
May-04-21	Initiated	RBC Capital Mkts	Sector Perform
Mar-01-21	Downgrade	Barclays	Overweight → Equal Weight
Feb-16-21	Initiated	Wells Fargo	Overweight
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-21	Initiated	Stifel	Hold
Aug-05-20	Initiated	William Blair	Outperform
Mar-02-20	Initiated	Barclays	Overweight
Mar-02-20	Initiated	JP Morgan	Overweight
Mar-02-20	Initiated	Jefferies	Buy
Mar-02-20	Initiated	Wedbush	Outperform

View All

Beam Therapeutics Inc Stock (BEAM) Latest News

Oct 12, 2025

Beam Therapeutics Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo

Oct 12, 2025

Oct 11, 2025

Beam Therapeutics (BEAM): Assessing Valuation After Fresh Buy Ratings, Clinical Updates, and Institutional Moves - Yahoo Finance

Oct 11, 2025

Jim Cramer on Beam Therapeutics: “That’s the Speculative Bottom There” - MSN

Oct 11, 2025

Beam Therapeutics (NASDAQ:BEAM) Earns "Buy" Rating from HC Wainwright - MarketBeat

Oct 11, 2025

Oct 10, 2025

Beam Therapeutics (NASDAQ:BEAM) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat

Oct 10, 2025

Does Beam Therapeutics Inc. qualify in momentum factor screeningJuly 2025 Macro Moves & Long-Term Growth Portfolio Plans - newser.com

Oct 10, 2025

Bristol Myers Squibb buys Cambridge biotech for $1.5B - The Business Journals

Oct 10, 2025

HC Wainwright & Co. Reiterates Beam Therapeutics (BEAM) Buy Recommendation - Nasdaq

Oct 10, 2025

HC Wainwright & Co. Reiterates Buy Rating for BEAM at $80 Target - GuruFocus

Oct 10, 2025

What the charts say about Beam Therapeutics Inc. today2025 Price Targets & Community Consensus Picks - newser.com

Oct 10, 2025

Oct 09, 2025

Beam Therapeutics (NASDAQ:BEAM) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat

Oct 09, 2025

Beam Therapeutics Stock Soars 7.44%, Hits Intraday High of $27.55 - Markets Mojo

Oct 09, 2025

Jefferies initiates Beam Therapeutics stock with Buy rating on upcoming catalysts By Investing.com - Investing.com Canada

Oct 09, 2025

Jefferies initiates Beam Therapeutics stock with Buy rating on upcoming catalysts - Investing.com Australia

Oct 09, 2025

Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts - FinancialContent

Oct 09, 2025

Jefferies Initiates Beam Therapeutics at Buy Rating, $41 Price Target - MarketScreener

Oct 09, 2025

Does Beam Therapeutics Inc. show high probability of reboundEntry Point & Step-by-Step Swing Trade Plans - newser.com

Oct 09, 2025

SteelPeak Wealth LLC Invests $391,000 in Beam Therapeutics Inc. $BEAM - MarketBeat

Oct 09, 2025

Technical analysis overview for Beam Therapeutics Inc. stockWatch List & Entry Point Confirmation Signals - newser.com

Oct 09, 2025

Sector ETF performance correlation with Beam Therapeutics Inc.Product Launch & Low Risk Investment Opportunities - newser.com

Oct 09, 2025

Is Beam Therapeutics Inc. stock entering bullish territoryPortfolio Update Summary & Real-Time Volume Analysis - newser.com

Oct 09, 2025

Oct 08, 2025

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects - ts2.tech

Oct 08, 2025

Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves - Benzinga

Oct 08, 2025

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences - FinancialContent

Oct 08, 2025

What Does Wall Street Think About Beam Therapeutics (BEAM)? - Yahoo Finance

Oct 08, 2025

Oct 06, 2025

Using Ichimoku Cloud for Beam Therapeutics Inc. technicalsQuarterly Profit Summary & Low Risk Entry Point Tips - newser.com

Oct 06, 2025

Oct 03, 2025

Recent Insider Transactions at Beam Therapeutics - TradingView

Oct 03, 2025

Beam Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo

Oct 03, 2025

Oct 01, 2025

Beam Therapeutics Shows Rising Price Performance With Jump To 81 RS Rating - MSN

Oct 01, 2025

Sep 29, 2025

Beam Therapeutics Inc Stock Analysis and ForecastGlobal Market Influence & Budget Friendly Capital Growth - earlytimes.in

Sep 29, 2025

What analysts say about Beam Therapeutics Inc stockRelative Strength Index (RSI) & Master Timing Market Moves - earlytimes.in

Sep 29, 2025

Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now? - MSN

Sep 29, 2025

Sep 28, 2025

H.C. Wainwright Maintains Buy on Beam (BEAM), $80 Target on Pipeline Momentum - MSN

Sep 28, 2025

Is Beam Therapeutics Inc a good long term investmentGrowth vs. Value Investing & Affordable Investment Portfolio - earlytimes.in

Sep 28, 2025

Sep 26, 2025